Science Updates

FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)

FDA Approves fam-Trastuzumab Deruxtecan-nxki with Pertuzumab for Unresectable or Metastatic HER2-positive Breast Cancer

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma

Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer — Final Results From HERIZON-BTC-01

mRNA-Based COVID Vaccines May Generate Improved Responses to Immunotherapy

Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher

First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF)